Emcure Pharmaceuticals Ltd Stock Price Today (NSE: EMCURE)
Fundamental Score
Emcure Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Emcure Pharmaceuticals Ltd share price today is ₹1725.70, down 0.54% on NSE/BSE as of 17 June 2026. Emcure Pharmaceuticals Ltd (EMCURE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹27.17K (Cr). The 52-week high for EMCURE share price is ₹1830.00 and the 52-week low is ₹1228.90. At a P/E ratio of 33.89x, EMCURE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 18.51% and a debt-to-equity ratio of 0.35.
Emcure Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Emcure Pharmaceuticals Ltd share price chart: 5.33% return over the past month. 52-week high ₹1830.00, 52-week low ₹1228.90.
Emcure Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1705.20 | ₹1713.70 | ₹1667.00 | ₹1704.40 | 1.41L (Cr) | |
| ₹1718.50 | ₹1747.30 | ₹1690.00 | ₹1705.20 | 68.59K (Cr) | |
| ₹1739.90 | ₹1750.00 | ₹1675.00 | ₹1696.00 | 2.30L (Cr) | |
| ₹1720.00 | ₹1730.70 | ₹1676.50 | ₹1725.30 | 1.46L (Cr) | |
| ₹1745.00 | ₹1756.00 | ₹1692.20 | ₹1698.50 | 1.08L (Cr) | |
| ₹1713.60 | ₹1740.90 | ₹1705.00 | ₹1738.30 | 75.78K (Cr) | |
| ₹1730.00 | ₹1752.70 | ₹1705.20 | ₹1713.60 | 70.09K (Cr) | |
| ₹1752.00 | ₹1757.90 | ₹1721.00 | ₹1751.50 | 72.52K (Cr) | |
| ₹1710.00 | ₹1756.90 | ₹1701.00 | ₹1734.00 | 1.08L (Cr) | |
| ₹1694.00 | ₹1723.80 | ₹1680.80 | ₹1710.20 | 1.45L (Cr) |
Emcure Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1718.50 | ₹1747.30 | ₹1667.00 | ₹1704.40 | -0.82% | |
| ₹1710.00 | ₹1830.00 | ₹1627.40 | ₹1696.00 | -0.82% | |
| ₹1660.00 | ₹1769.00 | ₹1457.00 | ₹1680.10 | +1.21% | |
| ₹1390.00 | ₹1671.80 | ₹1381.00 | ₹1595.50 | +14.78% | |
| ₹1505.30 | ₹1565.20 | ₹1386.30 | ₹1455.50 | -3.31% | |
| ₹1360.00 | ₹1585.60 | ₹1356.00 | ₹1463.80 | +7.63% | |
| ₹1419.80 | ₹1469.00 | ₹1360.20 | ₹1364.50 | -3.89% | |
| ₹1328.90 | ₹1463.70 | ₹1306.50 | ₹1414.30 | +6.43% | |
| ₹1260.00 | ₹1448.80 | ₹1260.00 | ₹1318.90 | +4.67% | |
| ₹1393.40 | ₹1409.90 | ₹1260.00 | ₹1279.90 | -8.15% | |
| ₹1402.50 | ₹1519.90 | ₹1317.00 | ₹1393.40 | -0.65% | |
| ₹1310.00 | ₹1458.00 | ₹1228.90 | ₹1409.60 | +7.60% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Emcure Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Emcure Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of EMCURE across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (18.51%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.72%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.45%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (25.13%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (34.92% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (36.18% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (9.74x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹2541.67 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 7.65%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Emcure Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Emcure Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Emcure Pharmaceuticals LtdEmcure Pharmace...Selected✓ EMCURE • 544210 | 68.4/100 | ₹1725.70₹1726 | ₹27173.01₹27173.01 | 33.89Average 33.9 Average | 18.51%Good 18.51% Good | 20.72%Excellent 20.72% Excellent | 0.35Excellent 0.3 Excellent | 36.18%Excellent 36.18% Excellent | 9.36%Good 9.36% Good | 0.21% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Emcure Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for EMCURE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹36.43 | ₹1364.50 | 37.5x |
| FY 2024 | ₹27.57 | ₹1447.10 | 52.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Emcure Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by EMCURE — dividend yield 0.21%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹54.26 Cr |
| FY 2023 | ₹36.17 Cr |
| FY 2022 | ₹54.26 Cr |
| FY 2021 | ₹18.09 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Emcure Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for EMCURE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
13.38%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
25.13%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.36%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
36.18%
Compounded annual net profit growth over 5 years
Emcure Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for EMCURE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Emcure Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Emcure Pharmaceuticals Ltd (EMCURE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Emcure Pharmaceuticals Ltd
About EMCURE (Emcure Pharmaceuticals Ltd)
Emcure Pharmaceuticals Ltd is a global pharmaceutical company committed to developing, manufacturing, and marketing a diverse portfolio of pharmaceutical products to improve patien...t outcomes worldwide. With a strong emphasis on innovation and quality, Emcure focuses on addressing unmet medical needs across a broad range of therapeutic areas, including women's health, oncology, and cardiovascular disease. The company leverages advanced technologies and a dedicated team of researchers to create effective and affordable treatment options for patients around the globe. Emcure’s dedication to ethical business practices and its commitment to corporate social responsibility have established it as a respected and reliable partner within the healthcare industry. Emcure operates across various specialized divisions, each focusing on specific therapeutic areas and patient populations. The company's extensive product line encompasses a wide range of dosage forms, including tablets, capsules, injectables, and topical formulations. Emcure emphasizes research and development to expand its product portfolio and cater to emerging market trends. The company's manufacturing facilities are equipped with state-of-the-art equipment and adhere to stringent quality control standards, ensuring that all products meet the highest levels of safety and efficacy. With a comprehensive distribution network, Emcure strives to make its medicines accessible to patients in diverse geographic locations. Emcure has established strategic alliances and collaborations to expand its global reach and enhance its product offerings. These partnerships allow Emcure to leverage external expertise and resources to accelerate the development and commercialization of novel therapies. The company also actively engages in educational initiatives to raise awareness of important health issues and promote the appropriate use of medications. Emcure's commitment to innovation, quality, and patient well-being drives its continued growth and reinforces its position as a leading pharmaceutical company dedicated to improving global health.
Company Details
Key Leadership
Corporate Events
Latest News
EMCURE Share Price: Frequently Asked Questions
What is the current share price of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd (EMCURE) trades at ₹1725.70 on NSE and BSE. Market cap ₹27.17K (Cr). Educational data only.
What is the P/E ratio of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd has a P/E of 33.89x vs industry average 31.77x.
What is the Bull Run score for Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd has a Bull Run score of 68.4/100 based on 25+ financial parameters.
Does Emcure Pharmaceuticals Ltd pay dividends?
Emcure Pharmaceuticals Ltd has a dividend yield of 0.21%. Past dividends don't guarantee future payments.
What is the ROE of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd has ROE of 18.51%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd has debt-to-equity of 0.35.
Is Emcure Pharmaceuticals Ltd a good investment?
Bull Run gives Emcure Pharmaceuticals Ltd a score of 68.4/100. This is not investment advice — consult a SEBI-registered advisor.